Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer

Erzsébet Valicsek, Renáta Kószó, Ágnes Dobi, Gabriella Uhercsák, Zoltán Varga, Andrea Vass, Éva Jebelovszky, Z. Kahán

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aim: Trastuzumab therapy, the standard treatment for human epidermal growth factor receptor type-2 (HER2)-positive breast cancer, is associated with possible cardiotoxicity. We set out to retrospectively analyze the cardiac follow-up data of patients with breast cancer receiving trastuzumab treatment. Patients and Methods: The study involved 47 and 31 patients receiving adjuvant or palliative chemotherapy plus trastuzumab, respectively. Cardiovascular system assessments including echocardiography were regularly performed. Results: A significant heart abnormality was detected in 44.7% of the operable and 41.9% of metastatic cases. In the adjuvant setting, left ventricular ejection fraction changes occurred mostly during treatment and less frequently after its completion (40.4% vs. 19.4%), while in the palliative setting, 35.5% and 40% in the first and the second year of therapy. An asymptomatic atrial septum aneurysm was detected in 8.5% and 13% of the patients in the two groups. Conclusion: Trastuzumab-related cardiotoxicity is mostly manifested in an asymptomatic decrease in left ventricular ejection fraction; hypertension, a high body mass index and left-sided irradiation are its predictors.

Original languageEnglish
Pages (from-to)4967-4974
Number of pages8
JournalAnticancer Research
Volume35
Issue number9
Publication statusPublished - Sep 1 2015

Fingerprint

Palliative Care
Breast Neoplasms
Stroke Volume
Atrial Septum
Therapeutics
Congenital Heart Defects
Cardiovascular System
Aneurysm
Echocardiography
Body Mass Index
Trastuzumab
Hypertension
Drug Therapy
Cardiotoxicity

Keywords

  • BMI
  • Cardiac dysfunction
  • Hypertension
  • Radiotherapy
  • Risk factor
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Valicsek, E., Kószó, R., Dobi, Á., Uhercsák, G., Varga, Z., Vass, A., ... Kahán, Z. (2015). Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer. Anticancer Research, 35(9), 4967-4974.

Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer. / Valicsek, Erzsébet; Kószó, Renáta; Dobi, Ágnes; Uhercsák, Gabriella; Varga, Zoltán; Vass, Andrea; Jebelovszky, Éva; Kahán, Z.

In: Anticancer Research, Vol. 35, No. 9, 01.09.2015, p. 4967-4974.

Research output: Contribution to journalArticle

Valicsek, E, Kószó, R, Dobi, Á, Uhercsák, G, Varga, Z, Vass, A, Jebelovszky, É & Kahán, Z 2015, 'Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer', Anticancer Research, vol. 35, no. 9, pp. 4967-4974.
Valicsek E, Kószó R, Dobi Á, Uhercsák G, Varga Z, Vass A et al. Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer. Anticancer Research. 2015 Sep 1;35(9):4967-4974.
Valicsek, Erzsébet ; Kószó, Renáta ; Dobi, Ágnes ; Uhercsák, Gabriella ; Varga, Zoltán ; Vass, Andrea ; Jebelovszky, Éva ; Kahán, Z. / Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer. In: Anticancer Research. 2015 ; Vol. 35, No. 9. pp. 4967-4974.
@article{e3f9ab63958b4cfe97a75752ccf87f9f,
title = "Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer",
abstract = "Background/Aim: Trastuzumab therapy, the standard treatment for human epidermal growth factor receptor type-2 (HER2)-positive breast cancer, is associated with possible cardiotoxicity. We set out to retrospectively analyze the cardiac follow-up data of patients with breast cancer receiving trastuzumab treatment. Patients and Methods: The study involved 47 and 31 patients receiving adjuvant or palliative chemotherapy plus trastuzumab, respectively. Cardiovascular system assessments including echocardiography were regularly performed. Results: A significant heart abnormality was detected in 44.7{\%} of the operable and 41.9{\%} of metastatic cases. In the adjuvant setting, left ventricular ejection fraction changes occurred mostly during treatment and less frequently after its completion (40.4{\%} vs. 19.4{\%}), while in the palliative setting, 35.5{\%} and 40{\%} in the first and the second year of therapy. An asymptomatic atrial septum aneurysm was detected in 8.5{\%} and 13{\%} of the patients in the two groups. Conclusion: Trastuzumab-related cardiotoxicity is mostly manifested in an asymptomatic decrease in left ventricular ejection fraction; hypertension, a high body mass index and left-sided irradiation are its predictors.",
keywords = "BMI, Cardiac dysfunction, Hypertension, Radiotherapy, Risk factor, Trastuzumab",
author = "Erzs{\'e}bet Valicsek and Ren{\'a}ta K{\'o}sz{\'o} and {\'A}gnes Dobi and Gabriella Uhercs{\'a}k and Zolt{\'a}n Varga and Andrea Vass and {\'E}va Jebelovszky and Z. Kah{\'a}n",
year = "2015",
month = "9",
day = "1",
language = "English",
volume = "35",
pages = "4967--4974",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer

AU - Valicsek, Erzsébet

AU - Kószó, Renáta

AU - Dobi, Ágnes

AU - Uhercsák, Gabriella

AU - Varga, Zoltán

AU - Vass, Andrea

AU - Jebelovszky, Éva

AU - Kahán, Z.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background/Aim: Trastuzumab therapy, the standard treatment for human epidermal growth factor receptor type-2 (HER2)-positive breast cancer, is associated with possible cardiotoxicity. We set out to retrospectively analyze the cardiac follow-up data of patients with breast cancer receiving trastuzumab treatment. Patients and Methods: The study involved 47 and 31 patients receiving adjuvant or palliative chemotherapy plus trastuzumab, respectively. Cardiovascular system assessments including echocardiography were regularly performed. Results: A significant heart abnormality was detected in 44.7% of the operable and 41.9% of metastatic cases. In the adjuvant setting, left ventricular ejection fraction changes occurred mostly during treatment and less frequently after its completion (40.4% vs. 19.4%), while in the palliative setting, 35.5% and 40% in the first and the second year of therapy. An asymptomatic atrial septum aneurysm was detected in 8.5% and 13% of the patients in the two groups. Conclusion: Trastuzumab-related cardiotoxicity is mostly manifested in an asymptomatic decrease in left ventricular ejection fraction; hypertension, a high body mass index and left-sided irradiation are its predictors.

AB - Background/Aim: Trastuzumab therapy, the standard treatment for human epidermal growth factor receptor type-2 (HER2)-positive breast cancer, is associated with possible cardiotoxicity. We set out to retrospectively analyze the cardiac follow-up data of patients with breast cancer receiving trastuzumab treatment. Patients and Methods: The study involved 47 and 31 patients receiving adjuvant or palliative chemotherapy plus trastuzumab, respectively. Cardiovascular system assessments including echocardiography were regularly performed. Results: A significant heart abnormality was detected in 44.7% of the operable and 41.9% of metastatic cases. In the adjuvant setting, left ventricular ejection fraction changes occurred mostly during treatment and less frequently after its completion (40.4% vs. 19.4%), while in the palliative setting, 35.5% and 40% in the first and the second year of therapy. An asymptomatic atrial septum aneurysm was detected in 8.5% and 13% of the patients in the two groups. Conclusion: Trastuzumab-related cardiotoxicity is mostly manifested in an asymptomatic decrease in left ventricular ejection fraction; hypertension, a high body mass index and left-sided irradiation are its predictors.

KW - BMI

KW - Cardiac dysfunction

KW - Hypertension

KW - Radiotherapy

KW - Risk factor

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84939646996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939646996&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 4967

EP - 4974

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -